Acadia Pharmaceuticals Inc. (ACAD)Healthcare | Biotechnology | San Diego, United States | NasdaqGS
18.62 USD
-0.79
(-4.070%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 6:40 a.m. EDT
The investment case here is a study in contrasts between a fundamentally resilient business and a technically distressed stock. On the fundamentals side, the company boasts exceptional profitability with a 35.7% return on equity and healthy margins, supported by a fortress-like balance sheet with minimal debt and substantial cash reserves. Revenue is growing at a respectable 16.4%, and the upcoming Alzheimer's psychosis data could serve as a major catalyst. However, the market has punished the stock heavily, dragging the price down 26% over the last nine years, which has created a massive disconnect between the intrinsic value and the trading price. This dislocation explains the bullish analyst consensus and the wide gap between the current price and the mean target. Yet, the short-term outlook remains precarious. The stock is trading below its 50-day and 200-day moving averages, and the options market is screaming caution, with traders buying insurance against further declines rather than betting on a rally. While the long-term thesis is strong due to the quality of the business and the potential for a re-rating, the immediate path is likely choppy and volatile as the market digests the recent losses before any new data can drive a sustained recovery. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.092469 |
| AutoARIMA | 0.097697 |
| AutoETS | 0.097698 |
| MSTL | 0.100586 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 2.78 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 2.28 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.652 |
| Revenue per Share | 6.689 |
| Market Cap | 3,188,412,160 |
| Trailing P/E | 8.35 |
| Forward P/E | 20.22 |
| Beta | 0.89 |
| Profit Margins | 33.42% |
| Website | https://acadia.com |
As of Oct. 10, 2026, 6:40 a.m. EDT: Speculators are positioning defensively with heavy put volume and open interest concentrated at strikes below the current price (14, 16, 17, 20), creating a significant 'floor' of downside protection. Conversely, call activity is sparse and skewed toward distant strikes (30, 32, 35, 37), indicating a lack of immediate bullish conviction despite some volume spikes at specific out-of-the-money levels. The implied volatility structure shows elevated premiums for deep out-of-the-money puts relative to calls, suggesting the market prices in a higher probability of a drop than a surge in the near term.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.10717571 |
| Address1 | 12,830 El Camino Real |
| Address2 | Suite 400 |
| All Time High | 58.72 |
| All Time Low | 0.65 |
| Ask | 21.17 |
| Ask Size | 1 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.8 - Buy |
| Average Daily Volume10 Day | 2,220,790 |
| Average Daily Volume3 Month | 1,850,382 |
| Average Volume | 1,850,382 |
| Average Volume10Days | 2,220,790 |
| Beta | 0.887 |
| Bid | 15.97 |
| Bid Size | 1 |
| Board Risk | 2 |
| Book Value | 7.591 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 1 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 18.62 |
| Current Ratio | 3.388 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 19.1 |
| Day Low | 18.39 |
| Debt To Equity | 5.652 |
| Display Name | Acadia Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,875,400 |
| Earnings Call Timestamp Start | 1,785,875,400 |
| Earnings Growth | 0.133 |
| Earnings Quarterly Growth | 0.181 |
| Earnings Timestamp | 1,785,873,600 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda | 98,392,000 |
| Ebitda Margins | 0.08641 |
| Enterprise To Ebitda | 23.637 |
| Enterprise To Revenue | 2.043 |
| Enterprise Value | 2,325,708,800 |
| Eps Current Year | 0.59504 |
| Eps Forward | 0.92072 |
| Eps Trailing Twelve Months | 2.23 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 858 558 2872 |
| Fifty Day Average | 26.2156 |
| Fifty Day Average Change | -7.595598 |
| Fifty Day Average Change Percent | -0.28973582 |
| Fifty Two Week Change Percent | -10.717571 |
| Fifty Two Week High | 30.96 |
| Fifty Two Week High Change | -12.339998 |
| Fifty Two Week High Change Percent | -0.39857876 |
| Fifty Two Week Low | 18.39 |
| Fifty Two Week Low Change | 0.23000145 |
| Fifty Two Week Low Change Percent | 0.012506876 |
| Fifty Two Week Range | 18.39 - 30.96 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,085,664,600,000 |
| Float Shares | 128,350,380 |
| Forward Eps | 0.92072 |
| Forward P E | 20.223305 |
| Free Cashflow | 68,647,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 796 |
| Fullday Change | -0.4300003 |
| Fullday Change Percent | -2.2153544 |
| Fullday Price | 18.62 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.62061 |
| Gross Profits | 706,656,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0033000002 |
| Held Percent Institutions | 0.99698997 |
| Implied Shares Outstanding | 171,235,870 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California. |
| Long Name | Acadia Pharmaceuticals Inc. |
| Market | us_market |
| Market Cap | 3,188,412,160 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_683713 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 380,484,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,378,283,212 |
| Number Of Analyst Opinions | 19 |
| Open | 19.02 |
| Operating Cashflow | 160,319,008 |
| Operating Margins | 0.12286 |
| Overall Risk | 4 |
| Payout Ratio | 0.0 |
| Peg Ratio | 50.86 |
| Phone | 858 558 2871 |
| Previous Close | 19.41 |
| Price Eps Current Year | 31.292015 |
| Price Hint | 2 |
| Price To Book | 2.452905 |
| Price To Sales Trailing12 Months | 2.8001835 |
| Profit Margins | 0.33416 |
| Quick Ratio | 3.107 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.8 |
| Region | US |
| Regular Market Change | -0.789999 |
| Regular Market Change Percent | -4.07006 |
| Regular Market Day High | 19.1 |
| Regular Market Day Low | 18.39 |
| Regular Market Day Range | 18.39 - 19.1 |
| Regular Market Open | 19.02 |
| Regular Market Previous Close | 19.41 |
| Regular Market Price | 18.62 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 2,139,853 |
| Return On Assets | 0.03637 |
| Return On Equity | 0.35743 |
| Revenue Growth | 0.164 |
| Revenue Per Share | 6.689 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 171,235,870 |
| Shares Percent Shares Out | 0.048 |
| Shares Short | 8,275,918 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 9,739,720 |
| Short Name | ACADIA Pharmaceuticals Inc. |
| Short Percent Of Float | 0.0759 |
| Short Ratio | 3.94 |
| Source Interval | 15 |
| State | CA |
| Symbol | ACAD |
| Target High Price | 37.0 |
| Target Low Price | 17.0 |
| Target Mean Price | 30.57895 |
| Target Median Price | 33.0 |
| Total Cash | 956,473,984 |
| Total Cash Per Share | 5.551 |
| Total Debt | 73,854,000 |
| Total Revenue | 1,138,643,968 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 2.23 |
| Trailing P E | 8.349776 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 24.1701 |
| Two Hundred Day Average Change | -5.5500984 |
| Two Hundred Day Average Change Percent | -0.22962663 |
| Type Disp | Equity |
| Volume | 2,139,853 |
| Website | https://acadia.com |
| Zip | 92,130 |